HomeAI · summaries
Storia in 8 fonti
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
usatoday.com
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.
- ·
cnbc.com
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.
- ·
huffpost.com
The FDA Approves Powerful HIV Prevention Drug
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.
- ·
upi.com
FDA approves long-lasting HIV-prevention drug - UPI.com
The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease.
- ·
scmp.com
US approves Gilead’s twice-yearly shot for HIV prevention
Lenacapavir was nearly 100 per cent effective in preventing HIV in clinical trials.
- ·
ansa.it
Fda Usa approva un nuovo farmaco per prevenire l'Aids - Sanità - Ansa.it
La Food and Drug Administration (Fda) americana ha approvato un nuovo farmaco che potrebbe contribuire a mettere fine all'epidemia di Aids. Si tratta di un'iniezione antivirale…
- ·
repubblica.it
Rivoluzione Hiv: la Fda approva le due iniezioni l’anno per prevenire l’infezione
Il lancio del lenacapavir potrà cambiare il corso dell’epidemia di Aids. Ma dovrà affrontare tuttavia i tagli proposti dall'amministrazione Trump ai finanziame…
- ·
fortune.com
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
The shot made by Gilead Sciences nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.